230 related articles for article (PubMed ID: 18092135)
1. Nonionic intravenous contrast agent does not cause clinically significant artifacts to 18F-FDG PET/CT in patients with lung cancer.
An YS; Sheen SS; Oh YJ; Hwang SC; Yoon JK
Ann Nucl Med; 2007 Dec; 21(10):585-92. PubMed ID: 18092135
[TBL] [Abstract][Full Text] [Related]
2. Integrated FDG-PET/CT compared with intravenous contrast-enhanced CT for evaluation of metastatic regional lymph nodes in patients with resectable early stage esophageal cancer.
Okada M; Murakami T; Kumano S; Kuwabara M; Shimono T; Hosono M; Shiozaki H
Ann Nucl Med; 2009 Jan; 23(1):73-80. PubMed ID: 19205841
[TBL] [Abstract][Full Text] [Related]
3. Application of intravenous contrast in PET/CT: does it really introduce significant attenuation correction error?
Yau YY; Chan WS; Tam YM; Vernon P; Wong S; Coel M; Chu SK
J Nucl Med; 2005 Feb; 46(2):283-91. PubMed ID: 15695788
[TBL] [Abstract][Full Text] [Related]
4. The influence of different contrast medium concentrations and injection protocols on quantitative and clinical assessment of FDG-PET/CT in lung cancer.
Verburg FA; Kuhl CK; Pietsch H; Palmowski M; Mottaghy FM; Behrendt FF
Eur J Radiol; 2013 Oct; 82(10):e617-22. PubMed ID: 23880426
[TBL] [Abstract][Full Text] [Related]
5. The value of dual time point (18)F-FDG PET imaging for the differentiation between malignant and benign lesions.
Lan XL; Zhang YX; Wu ZJ; Jia Q; Wei H; Gao ZR
Clin Radiol; 2008 Jul; 63(7):756-64. PubMed ID: 18555033
[TBL] [Abstract][Full Text] [Related]
6. PET/CT with intravenous contrast can be used for PET attenuation correction in cancer patients.
Berthelsen AK; Holm S; Loft A; Klausen TL; Andersen F; Højgaard L
Eur J Nucl Med Mol Imaging; 2005 Oct; 32(10):1167-75. PubMed ID: 15909196
[TBL] [Abstract][Full Text] [Related]
7. Feasibility of [18F]FDG-PET and coregistered CT on clinical target volume definition of advanced non-small cell lung cancer.
Messa C; Ceresoli GL; Rizzo G; Artioli D; Cattaneo M; Castellone P; Gregorc V; Picchio M; Landoni C; Fazio F
Q J Nucl Med Mol Imaging; 2005 Sep; 49(3):259-66. PubMed ID: 16172572
[TBL] [Abstract][Full Text] [Related]
8. Dual-time-point F-18 FDG PET/CT for evaluation of intrathoracic lymph nodes in patients with non-small cell lung cancer.
Shinya T; Rai K; Okumura Y; Fujiwara K; Matsuo K; Yonei T; Sato T; Watanabe K; Kawai H; Sato S; Kanazawa S
Clin Nucl Med; 2009 Apr; 34(4):216-21. PubMed ID: 19300050
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis supporting algorithm for lymph node metastases from colorectal carcinoma on 18F-FDG PET/CT.
Inoue K; Sato T; Kitamura H; Ito M; Tsunoda Y; Hirayama A; Kurosawa H; Tanaka T; Fukushi M; Moriyama N; Fujii H
Ann Nucl Med; 2008 Jan; 22(1):41-8. PubMed ID: 18250986
[TBL] [Abstract][Full Text] [Related]
10. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
[TBL] [Abstract][Full Text] [Related]
11. Response assessment of colorectal liver metastases with contrast enhanced CT/18F-FDG PET.
García Vicente AM; Domínguez Ferreras E; Sánchez Pérez V; Poblete García VM; Villa Guzmán JC; Jiménez Aragón F; Pineda Pineda MD; Molino Trinidad C; Soriano Castrejón Á
Eur J Radiol; 2013 Jun; 82(6):e255-61. PubMed ID: 23414715
[TBL] [Abstract][Full Text] [Related]
12. [F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma.
Jadvar H; Henderson RW; Conti PS
J Comput Assist Tomogr; 2007; 31(2):223-8. PubMed ID: 17414758
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.
Yoo IeR; Chung SK; Park HL; Choi WH; Kim YK; Lee KY; Wang YP
Biomed Mater Eng; 2014; 24(6):3091-103. PubMed ID: 25227018
[TBL] [Abstract][Full Text] [Related]
14. Optimized intravenous contrast administration for diagnostic whole-body 18F-FDG PET/CT.
Beyer T; Antoch G; Bockisch A; Stattaus J
J Nucl Med; 2005 Mar; 46(3):429-35. PubMed ID: 15750155
[TBL] [Abstract][Full Text] [Related]
15. Integrated fluorine-18 fluorodeoxyglucose (18F-FDG) PET/CT compared to standard contrast-enhanced CT for characterization and staging of pulmonary tumors eligible for surgical resection.
Quaia E; Tona G; Gelain F; Lubin E; Pizzolato R; Boscolo E; Bussoli L
Acta Radiol; 2008 Nov; 49(9):995-1004. PubMed ID: 18651256
[TBL] [Abstract][Full Text] [Related]
16. Determination of vitality of liver lesions by alveolar echinococcosis. Comparison of parametric contrast enhanced ultrasound (SonoVue®) with quantified 18F-FDG-PET-CT.
Kaltenbach TE; Graeter T; Mason RA; Kratzer W; Oeztuerk S; Haenle MM; Gruener B; Gottstein M
Nuklearmedizin; 2015; 54(1):43-9. PubMed ID: 25423884
[TBL] [Abstract][Full Text] [Related]
17. Assessment of combination of contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography for evaluation of ovarian masses.
Tsuboyama T; Tatsumi M; Onishi H; Nakamoto A; Kim T; Hori M; Sakane M; Hori Y; Morii E; Hatazawa J; Tomiyama N
Invest Radiol; 2014 Aug; 49(8):524-31. PubMed ID: 24637584
[TBL] [Abstract][Full Text] [Related]
18. [The application of 18F-fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer].
Xu HF; Liu Y; Zhang JH; Zhou RS; Zhou FH; Yuan MH
Zhonghua Jie He He Hu Xi Za Zhi; 2005 Feb; 28(2):108-11. PubMed ID: 15854393
[TBL] [Abstract][Full Text] [Related]
19. Impact of FDG PET on the management of TBC treatment. A pilot study.
Sathekge M; Maes A; Kgomo M; Stoltz A; Pottel H; Van de Wiele C
Nuklearmedizin; 2010; 49(1):35-40. PubMed ID: 20162246
[TBL] [Abstract][Full Text] [Related]
20. The Role of 18F-FDG PET/CT in the evaluation of Ascites of Undetermined Origin.
Zhang M; Jiang X; Zhang M; Xu H; Zhai G; Li B
J Nucl Med; 2009 Apr; 50(4):506-12. PubMed ID: 19289438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]